文献速递泌尿男性生殖肿瘤

DNA修复基因克隆性造血干扰前列腺癌cfDNA检测

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
PubMed 文献 · JAMA Oncol · 2021-01-01

该病例系列纳入69例晚期前列腺癌患者,采用UW-OncoPlexCT panel进行cfDNA变异检测并配对全血对照。19%患者cfDNA中检出≥2%变异分数的CHIP变异,10%的CHIP变异位于PARPi资格相关DNA修复基因(ATM、BRCA2、CHEK2),CHIP变异占所检出体细胞DNA修复基因变异的近一半,且与年龄呈指数相关(R2=0.82)。配对全血对照可区分CHIP与肿瘤变异。

要点

  • 晚期前列腺癌cfDNA检测中约10%存在DNA修复基因CHIP干扰,最常见为ATM。
  • CHIP变异占cfDNA检出的体细胞DNA修复基因变异近一半,可导致PARPi资格误判。
  • 临床cfDNA检测应配对全血对照以排除CHIP变异,避免误诊。

核心结论

  • 约10%的晚期前列腺癌患者cfDNA中存在用于PARPi资格的DNA修复基因CHIP干扰,最常见为ATM。
  • 临床cfDNA检测应包含配对全血对照以排除CHIP变异并避免误诊。

研究设计与样本

  • 病例系列研究,纳入69例晚期前列腺癌患者(转移性疾病或局部治疗后PSA升高)。
  • 采用UW-OncoPlexCT大panel癌症二代测序检测cfDNA变异,并配对全血对照样本以确定变异来源。
  • 研究在学术医学中心系统参考实验室开展。

主要发现

  • 69例中13例(19%;95% CI,10%-30%)cfDNA检出变异分数≥2%的CHIP变异。
  • 7例(10%;95% CI,4%-20%)CHIP变异位于PARPi资格相关DNA修复基因,包括ATM(n=5)、BRCA2(n=1)、CHEK2(n=1)。
  • CHIP变异占所检出体细胞DNA修复基因变异的近一半。
  • CHIP变异与年龄呈指数相关(R2=0.82)。
  • 配对全血对照可区分CHIP干扰变异与前列腺癌变异。

关键数值与推荐

  • CHIP变异判定阈值为cfDNA中变异分数≥2%。
  • PARPi资格相关DNA修复基因CHIP变异发生率10%(95% CI,4%-20%)。

临床怎么用

  • 对晚期前列腺癌患者进行cfDNA检测时,应配对全血对照以排除CHIP变异。
  • 解读DNA修复基因变异(尤其ATM)用于PARPi资格判断时需警惕CHIP干扰,避免误诊。

局限性

  • 为病例系列研究,样本量69例,结论需更大规模研究验证。
  • 研究在单一学术医学中心系统参考实验室开展,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cell-free DNA (cfDNA) testing is increasingly used in the treatment of patients with advanced prostate cancer. Clonal hematopoiesis of indeterminate potential (CHIP) can interfere with cfDNA testing and cause incorrect interpretation of results. There is an urgent need to better understand this problem following recent US Food and Drug Administration approval of poly(ADP) ribose polymerase inhibitors (PARPi) for metastatic prostate cancer based on variants in DNA repair genes that can be affected by CHIP. OBJECTIVE: To determine the prevalence of clinically relevant CHIP interference in prostate cancer cfDNA testing. DESIGN, SETTING, AND PARTICIPANTS: We report a case series of 69 patients with advanced prostate cancer (metastatic disease or with rising PSA following localized therapy) who had cfDNA variant testing with a large panel cancer next generation sequencing assay (UW-OncoPlexCT). To determine the source of variants in plasma, we tested paired cfDNA and whole blood control samples. The study was carried out in an academic medical center system reference laboratory. MAIN OUTCOMES AND MEASURES: Prevalence and gene spectrum of CHIP interference in patients with prostate cancer undergoing cfDNA testing. RESULTS: We detected CHIP variants at 2% or more variant fraction in cfDNA from 13 of 69 men with prostate cancer (19%; 95% CI, 10%-30%). Seven men (10%; 95% CI, 4%-20%) had CHIP variants in DNA repair genes used to determine PARPi candidacy, including ATM (n = 5), BRCA2 (n = 1), and CHEK2 (n = 1). Overall, CHIP variants accounted for almost half of the somatic DNA repair gene variants detected. Participant CHIP variants were exponentially correlated with older age (R2 = 0.82). CHIP interference variants could be distinguished from prostate cancer variants using a paired whole-blood control. CONCLUSIONS AND RELEVANCE: In this case series, approximately 10% of men with advanced prostate cancer had CHIP interference in plasma cfDNA in DNA repair genes that are used for eligibility of PARPi therapy, most frequently in ATM. Clinical cfDNA testing should include a paired whole-blood control to exclude CHIP variants and avoid misdiagnosis.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Jensen K, Konnick EQ, Schweizer MT, et al. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. JAMA Oncol. 2021. PMID: 33151258. doi:10.1001/jamaoncol.2020.5161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。